How Smart Investors Look at Roivant Sciences (ROIV).

By Tamara Parker • Tuesday, June 20 09:44 • Permanent Link

Mid-cap Health Care company Roivant Sciences has moved -1.4% so far today on a volume of 177,302, compared to its average of 3,167,067. In contrast, the S&P 500 index moved -0.0%.

Roivant Sciences trades -29.83% away from its average analyst target price of $13.56 per share. The 8 analysts following the stock have set target prices ranging from $10.0 to $19.0, and on average have given Roivant Sciences a rating of buy.

If you are considering an investment in ROIV, you'll want to know the following:

Roivant Sciences has moved 126.0% over the last year, and the S&P 500 logged a change of 17.1%
Based on its trailing earnings per share of -1.77, Roivant Sciences has a trailing 12 month Price to Earnings (P/E) ratio of -5.4 while the S&P 500 average is 15.97
ROIV has a forward P/E ratio of -7.2 based on its forward 12 month price to earnings (EPS) of $-1.33 per share
Its Price to Book (P/B) ratio is 7.24 compared to its sector average of 4.16
Roivant Sciences Ltd. focuses on discovery, development, and commercialization of medicines.
Based in London, the company has 863 full time employees and a market cap of $7.22 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.